The potential role of human islet amyloid polypeptide in type 2 diabetes mellitus and Alzheimer’s diseases

[1]  Ali I. Al-Gareeb,et al.  Effects of neprilysin and neprilysin inhibitors on glucose homeostasis: Controversial points and a promising arena , 2023, Journal of diabetes.

[2]  Ali I. Al-Gareeb,et al.  Long-term use of metformin and Alzheimer’s disease: beneficial or detrimental effects , 2023, Inflammopharmacology.

[3]  Chuang Guo,et al.  The human islet amyloid polypeptide reduces hippocampal tauopathy and behavioral impairments in P301S mice without inducing neurotoxicity or seeding amyloid aggregation , 2023, Experimental Neurology.

[4]  Ali I. Al-Gareeb,et al.  Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure , 2022, Journal of diabetes.

[5]  Ali I. Al-Gareeb,et al.  Benzodiazepines in Alzheimer’s disease: beneficial or detrimental effects , 2022, Inflammopharmacology.

[6]  Ali I. Al-Gareeb,et al.  A Potential Link Between Visceral Obesity and Risk of Alzheimer’s Disease , 2022, Neurochemical Research.

[7]  T. Sakmar,et al.  Human Islet Amyloid Polypeptide (hIAPP) Protofibril‐Specific Antibodies for Detection and Treatment of Type 2 Diabetes , 2022, Advanced science.

[8]  Ali I. Al-Gareeb,et al.  Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy? , 2022, Inflammopharmacology.

[9]  Ali I. Al-Gareeb,et al.  Statins Use in Alzheimer Disease: Bane or Boon from Frantic Search and Narrative Review , 2022, Brain sciences.

[10]  Lucie Khemtemourian,et al.  Targeting hIAPP fibrillation: A new paradigm to prevent β-cell death? , 2022, Biochimica et biophysica acta. Biomembranes.

[11]  Dan Zhang,et al.  Association Between Metformin and Alzheimer's Disease: A Systematic Review and Meta-Analysis of Clinical Observational Studies. , 2022, Journal of Alzheimer's disease : JAD.

[12]  Shilpy Sharma,et al.  Human islet amyloid polypeptide: A therapeutic target for the management of type 2 diabetes mellitus , 2022, Journal of pharmaceutical analysis.

[13]  K. White,et al.  Factors That Contribute to hIAPP Amyloidosis in Type 2 Diabetes Mellitus , 2022, Life.

[14]  F. D. De Felice,et al.  Impaired insulin signalling and allostatic load in Alzheimer disease , 2022, Nature Reviews Neuroscience.

[15]  Cheng Hu,et al.  Common variants in genes involved in islet amyloid polypeptide (IAPP) processing and the degradation pathway are associated with T2DM risk: A Chinese population study. , 2022, Diabetes research and clinical practice.

[16]  Keyvan Yousefi,et al.  Metformin in Alzheimer's disease: An overview of potential mechanisms, preclinical and clinical findings. , 2022, Biochemical pharmacology.

[17]  Zhentao Zhang,et al.  Islet amyloid polypeptide cross-seeds tau and drives the neurofibrillary pathology in Alzheimer’s disease , 2022, Molecular neurodegeneration.

[18]  A. Sahebkar,et al.  Mechanistic insight into the role of metformin in Alzheimer's disease. , 2022, Life sciences.

[19]  Tian Li,et al.  Exploring the dual character of metformin in Alzheimer's disease , 2022, Neuropharmacology.

[20]  Y. Kitagishi,et al.  Neuroprotection by dipeptidyl-peptidase-4 inhibitors and glucagon-like peptide-1 analogs via the modulation of AKT-signaling pathway in Alzheimer’s disease , 2021, World journal of biological chemistry.

[21]  P. Manzine,et al.  Metformin a Potential Pharmacological Strategy in Late Onset Alzheimer’s Disease Treatment , 2021, Pharmaceuticals.

[22]  Ali I. Al-Gareeb,et al.  Impact of Sitagliptin in Non-Diabetic Covid-19 Patients. , 2021, Current molecular pharmacology.

[23]  Y. Ando,et al.  Metformin attenuates vascular pathology by increasing expression of insulin-degrading enzyme in a mixed model of cerebral amyloid angiopathy and type 2 diabetes mellitus , 2021, Neuroscience Letters.

[24]  Tingjun Hou,et al.  Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model , 2021, Protein & Cell.

[25]  S. Lipton,et al.  Protein S-nitrosylation and oxidation contribute to protein misfolding in neurodegeneration. , 2021, Free radical biology & medicine.

[26]  Bikash R. Sahoo,et al.  Investigation of the effects of two major secretory granules components, insulin and zinc, on human-IAPP amyloid aggregation and membrane damage. , 2021, Chemistry and physics of lipids.

[27]  L. Hiebert.  Heparan Sulfate Proteoglycans in Diabetes , 2021, Seminars in Thrombosis and Hemostasis.

[28]  G. Tundo,et al.  The interplay between lipid and Aβ amyloid homeostasis in Alzheimer's Disease: risk factors and therapeutic opportunities. , 2021, Chemistry and physics of lipids.

[29]  M. Leissring,et al.  Targeting Insulin-Degrading Enzyme in Insulin Clearance , 2021, International journal of molecular sciences.

[30]  S. Radford,et al.  Proteostasis of Islet Amyloid Polypeptide: A Molecular Perspective of Risk Factors and Protective Strategies for Type II Diabetes. , 2021, Chemical reviews.

[31]  J. Hardy,et al.  The association of circulating amylin with β‐amyloid in familial Alzheimer's disease , 2021, Alzheimer's & dementia.

[32]  I. Martins,et al.  Islet amyloid polypeptide & amyloid beta peptide roles in Alzheimer’s disease: two triggers, one disease , 2020, Neural regeneration research.

[33]  Yung Chang,et al.  Introduction and Fundamentals of Human Islet Amyloid Polypeptide Inhibitors. , 2020, ACS applied bio materials.

[34]  G. Farrugia,et al.  The Human Islet Amyloid Polypeptide in Protein Misfolding Disorders: Mechanisms of Aggregation and Interaction with Biomembranes. , 2020, Chemistry and physics of lipids.

[35]  Md. Farhad Hossain,et al.  Anti-Neuroinflammatory Potential of Polyphenols by Inhibiting NF-κB to Halt Alzheimer's Disease. , 2020, Current pharmaceutical design.

[36]  B. Duncan,et al.  Markers of adiposity, insulin resistance, prediabetes and cognitive function at baseline of the Brazilian Longitudinal Study of Adult Health (ELSA - Brasil). , 2020, Diabetes research and clinical practice.

[37]  Ashutosh Kumar,et al.  Myricetin protects pancreatic β-cells from human islet amyloid polypeptide (hIAPP) induced cytotoxicity and restores islet function , 2020, Biological chemistry.

[38]  Ashutosh Kumar,et al.  Human islet amyloid polypeptide (hIAPP) - a curse in type II diabetes mellitus: insights from structure and toxicity studies , 2020, Biological chemistry.

[39]  D. Raleigh,et al.  Low concentration IL-1β promotes islet amyloid formation by increasing hIAPP release from humanised mouse islets in vitro , 2020, Diabetologia.

[40]  Z. Xie,et al.  Multifunctional roles of zinc in Alzheimer's disease. , 2020, Neurotoxicology.

[41]  Ali I. Al-Gareeb,et al.  Metformin and/or vildagliptin mitigate type II diabetes mellitus induced-oxidative stress: The intriguing effect , 2020, Journal of advanced pharmaceutical technology & research.

[42]  Bikash R. Sahoo,et al.  Amylin and beta amyloid proteins interact to form amorphous heterocomplexes with enhanced toxicity in neuronal cells , 2020, Scientific Reports.

[43]  Hayder M Al-Kuraishy,et al.  Oxidative stress injury and glucolipotoxicity in type 2 diabetes mellitus: The potential role of metformin and sitagliptin , 2020, Biomedical and Biotechnology Research Journal (BBRJ).

[44]  M. Garg,et al.  Dietary Supplementation with Curcumin Reduce Circulating Levels of Glycogen Synthase Kinase-3β and Islet Amyloid Polypeptide in Adults with High Risk of Type 2 Diabetes and Alzheimer’s Disease , 2020, Nutrients.

[45]  J. Merayo-Lloves,et al.  Heparan Sulfate Proteoglycans Undergo Differential Expression Alterations in Alzheimer Disease Brains. , 2020, Journal of neuropathology and experimental neurology.

[46]  I. Martins,et al.  Islet Amyloid Polypeptide: A Partner in Crime With Aβ in the Pathology of Alzheimer's Disease , 2020, Frontiers in Molecular Neuroscience.

[47]  Jiaojiao Zheng,et al.  Non-polyphenolic natural inhibitors of amyloid aggregation. , 2020, European journal of medicinal chemistry.

[48]  A. Barron,et al.  The Human Host‐Defense Peptide Cathelicidin LL‐37 is a Nanomolar Inhibitor of Amyloid Self‐Assembly of Islet Amyloid Polypeptide (IAPP) , 2020, Angewandte Chemie.

[49]  A. Alamri,et al.  The status of zinc in type 2 diabetic patients and its association with glycemic control , 2020, Journal of family & community medicine.

[50]  A. Tanskanen,et al.  Metformin and risk of Alzheimer's disease among community-dwelling people with diabetes: a national case-control study. , 2019, The Journal of clinical endocrinology and metabolism.

[51]  H. Lebovitz.  Thiazolidinediones: the Forgotten Diabetes Medications , 2019, Current Diabetes Reports.

[52]  H. Ouyang,et al.  Preparation of a new type 2 diabetic miniature pig model via the CRISPR/Cas9 system , 2019, Cell Death & Disease.

[53]  J. Issberner,et al.  A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer’s Disease in transgenic mice , 2019, Behavioural Brain Research.

[54]  Ali I. Al-Gareeb,et al.  Effects of diabetic pharmacotherapy on prolactin hormone in patients with type 2 diabetes mellitus: Bane or Boon , 2019, Journal of advanced pharmaceutical technology & research.

[55]  P. Simos,et al.  Neurocognitive impairment in type 2 diabetes mellitus , 2019, Hormones.

[56]  M. Hayden.  Type 2 Diabetes Mellitus Increases the Risk of Late-Onset Alzheimer’s Disease: Ultrastructural Remodeling of the Neurovascular Unit and Diabetic Gliopathy , 2019, Brain sciences.

[57]  Ali I. Al-Gareeb,et al.  Metabolic profile and prolactin serum levels in men with type 2 diabetes mellitus: Old-new rubric , 2019, International journal of critical illness and injury science.

[58]  L. Minthon,et al.  Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer’s disease , 2019, PloS one.

[59]  T. P. Davis,et al.  Probing the Aggregation and Immune Response of Human Islet Amyloid Polypeptides with Ligand-Stabilized Gold Nanoparticles. , 2019, ACS applied materials & interfaces.

[60]  R. Chakrabarti,et al.  Azadirachtin inhibits amyloid formation, disaggregates pre-formed fibrils and protects pancreatic β-cells from human islet amyloid polypeptide/amylin-induced cytotoxicity. , 2019, The Biochemical journal.

[61]  L. Kabasakal,et al.  The methanolic extract of Thymus praecox subsp. skorpilii var. skorpilii restores glucose homeostasis, ameliorates insulin resistance and improves pancreatic β-cell function on streptozotocin/nicotinamide-induced type 2 diabetic rats. , 2019, Journal of ethnopharmacology.

[62]  Kun Huang,et al.  Glycated Insulin Exacerbates the Cytotoxicity of Human Islet Amyloid Polypeptides: a Vicious Cycle in Type 2 Diabetes. , 2019, ACS chemical biology.

[63]  S. Kahn,et al.  Loss of perlecan heparan sulfate glycosaminoglycans lowers body weight and decreases islet amyloid deposition in human islet amyloid polypeptide transgenic mice. , 2019, Protein engineering, design & selection : PEDS.

[64]  E. Kang,et al.  Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and β-Cell Function in Type 2 Diabetes Mellitus: A Propensity Score-Matched Analysis , 2018, Diabetes Therapy.

[65]  Ke Li,et al.  Influence of ADAM10 Polymorphisms on Plasma Level of Soluble Receptor for Advanced Glycation End Products and The Association With Alzheimer’s Disease Risk , 2018, Front. Genet..

[66]  Ali I. Al-Gareeb,et al.  Sulfonylurea and neuroprotection: The bright side of the moon , 2018, Journal of advanced pharmaceutical technology & research.

[67]  D. Milardi,et al.  Amyloid growth and membrane damage: Current themes and emerging perspectives from theory and experiments on Aβ and hIAPP. , 2018, Biochimica et biophysica acta. Biomembranes.

[68]  Hayder M Al-Kuraishy,et al.  Differential effect of metformin and/or glyburide on apelin serum levels in patients with type 2 diabetes mellitus: Concepts and clinical practice , 2018, Journal of advanced pharmaceutical technology & research.

[69]  D. Eisenberg,et al.  Common fibrillar spines of amyloid-β and human islet amyloid polypeptide revealed by microelectron diffraction and structure-based inhibitors , 2017, The Journal of Biological Chemistry.

[70]  B. Winblad,et al.  Tau hyperphosphorylation induces oligomeric insulin accumulation and insulin resistance in neurons , 2017, Brain : a journal of neurology.

[71]  P. Fraser,et al.  Amyloid‐β and islet amyloid pathologies link Alzheimer’s disease and type 2 diabetes in a transgenic model , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[72]  L. Buée,et al.  Tau deletion promotes brain insulin resistance , 2017, The Journal of experimental medicine.

[73]  Weihong Song,et al.  Islet amyloid polypeptide: Another key molecule in Alzheimer’s pathogenesis? , 2017, Progress in Neurobiology.

[74]  J. Detre,et al.  Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-controlled Crossover Study , 2017, Alzheimer disease and associated disorders.

[75]  P. Butler,et al.  β Cell-specific increased expression of calpastatin prevents diabetes induced by islet amyloid polypeptide toxicity. , 2016, JCI insight.

[76]  A. Politis,et al.  [Pro-inflammatory cytokines in Alzheimer's disease]. , 2016, Psychiatrike = Psychiatriki.

[77]  D. Eliezer,et al.  Inhibition of Human Islet Amyloid Polypeptide Aggregation in Type 2 Diabetes by Hsp70 Molecular Chaperones , 2016 .

[78]  E. Vidoni,et al.  Cognitively impaired elderly exhibit insulin resistance and no memory improvement with infused insulin , 2016, Neurobiology of Aging.

[79]  T. P. Davis,et al.  Pancreatic β-Cell Membrane Fluidity and Toxicity Induced by Human Islet Amyloid Polypeptide Species , 2016, Scientific Reports.

[80]  Wei-Jen Tang.  Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus , 2016, Trends in Endocrinology & Metabolism.

[81]  Erol Cerasi,et al.  Autophagy is a major regulator of beta cell insulin homeostasis , 2016, Diabetologia.

[82]  J. Ehses,et al.  Differential Activation of Innate Immune Pathways by Distinct Islet Amyloid Polypeptide (IAPP) Aggregates* , 2016, The Journal of Biological Chemistry.

[83]  S. An,et al.  Causative factors for formation of toxic islet amyloid polypeptide oligomer in type 2 diabetes mellitus , 2015, Clinical interventions in aging.

[84]  O. Erbaş,et al.  Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats. , 2015, European journal of pharmacology.

[85]  Bin-bo Jiang,et al.  Cross-Seeding Interaction between β-Amyloid and Human Islet Amyloid Polypeptide. , 2015, ACS chemical neuroscience.

[86]  M. Ingelsson,et al.  In vivo seeding and cross-seeding of localized amyloidosis: a molecular link between type 2 diabetes and Alzheimer disease. , 2015, The American journal of pathology.

[87]  J. Brender,et al.  Probing the sources of the apparent irreproducibility of amyloid formation: drastic changes in kinetics and a switch in mechanism due to micellelike oligomer formation at critical concentrations of IAPP. , 2015, The journal of physical chemistry. B.

[88]  J. Jhamandas,et al.  Islet amyloid polypeptide (IAPP): a second amyloid in Alzheimer's disease. , 2014, Current Alzheimer research.

[89]  Marta S. Fernández.  Human IAPP amyloidogenic properties and pancreatic β-cell death. , 2014, Cell calcium.

[90]  Xinglong Wang,et al.  Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. , 2014, Biochimica et biophysica acta.

[91]  David R. Liu,et al.  Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones , 2014, Nature.

[92]  N. Amdursky,et al.  Apoptosis induced by islet amyloid polypeptide soluble oligomers is neutralized by diabetes-associated specific antibodies , 2014, Scientific Reports.

[93]  C. Jack,et al.  Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias , 2014, Alzheimer's Research & Therapy.

[94]  M. Stefani,et al.  Mild exposure of RIN-5F β-cells to human islet amyloid polypeptide aggregates upregulates antioxidant enzymes via NADPH oxidase-RAGE: An hormetic stimulus☆ , 2013, Redox biology.

[95]  C. DeCarli,et al.  Amylin deposition in the brain: A second amyloid in Alzheimer disease? , 2013, Annals of Neurology.

[96]  R. Holsinger,et al.  Saxagliptin: A dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease , 2013, Neuropharmacology.

[97]  J. Götz,et al.  Lessons from two prevalent amyloidoses—what amylin and Aβ have in common , 2013, Front. Aging Neurosci..

[98]  Craig E. Nelson,et al.  Effects of Heparin on Amylin Fibrillization , 2012 .

[99]  Alicia R. Desilets,et al.  Rosiglitazone and Pioglitazone for the Treatment of Alzheimer's Disease , 2011, The Annals of pharmacotherapy.

[100]  M. Soty,et al.  Involvement of ATP-sensitive Potassium (KATP) Channels in the Loss of Beta-cell Function Induced by Human Islet Amyloid Polypeptide* , 2011, The Journal of Biological Chemistry.

[101]  N. Van Rooijen,et al.  IL-1 Blockade Attenuates Islet Amyloid Polypeptide-Induced Proinflammatory Cytokine Release and Pancreatic Islet Graft Dysfunction , 2011, The Journal of Immunology.

[102]  H. Soininen,et al.  AMP‐activated protein kinase: a potential player in Alzheimer’s disease , 2011, Journal of neurochemistry.

[103]  J. Brender,et al.  A two-site mechanism for the inhibition of IAPP amyloidogenesis by zinc. , 2011, Journal of molecular biology.

[104]  Per Westermark,et al.  Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. , 2011, Physiological reviews.

[105]  D. Moffet,et al.  Selection for nonamyloidogenic mutants of islet amyloid polypeptide (IAPP) identifies an extended region for amyloidogenicity. , 2010, Biochemistry.

[106]  Hong Qing,et al.  Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes , 2010, Neurobiology of Aging.

[107]  Michael Gold,et al.  Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study , 2010, Dementia and Geriatric Cognitive Disorders.

[108]  J. Brender,et al.  Role of zinc in human islet amyloid polypeptide aggregation. , 2010, Journal of the American Chemical Society.

[109]  A. Esteghamati,et al.  Increased serum HSP70 levels are associated with the duration of diabetes , 2010, Cell Stress and Chaperones.

[110]  G. Paolisso,et al.  Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice , 2010, Experimental Gerontology.

[111]  H. Reber,et al.  Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. , 2010, The American journal of pathology.

[112]  I. Shimomura,et al.  Role of copper ion in the pathogenesis of type 2 diabetes. , 2009, Endocrine journal.

[113]  S. Dry,et al.  Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes , 2009, Diabetes.

[114]  Y. Zick,et al.  Phosphorylation of IRS proteins, insulin action, and insulin resistance. , 2009, American journal of physiology. Endocrinology and metabolism.

[115]  Niccolò Taddei,et al.  Aggregation Propensity of the Human Proteome , 2008, PLoS Comput. Biol..

[116]  T. Hughes,et al.  DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with β-cell-specific overexpression of human islet amyloid polypeptide , 2007, Regulatory Peptides.

[117]  S. Knuutila,et al.  Impairment of the Ubiquitin-Proteasome Pathway Is a Downstream Endoplasmic Reticulum Stress Response Induced by Extracellular Human Islet Amyloid Polypeptide and Contributes to Pancreatic β-Cell Apoptosis , 2007, Diabetes.

[118]  Stanislaus S. Wong,et al.  Aromatic interactions are not required for amyloid fibril formation by islet amyloid polypeptide but do influence the rate of fibril formation and fibril morphology. , 2007, Biochemistry.

[119]  R. Rydel,et al.  α2β1 and αVβ1 integrin signaling pathways mediate amyloid-β-induced neurotoxicity , 2007, Neurobiology of Aging.

[120]  R. Green,et al.  Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. , 2006, Archives of neurology.

[121]  E. Gazit,et al.  Molecular mapping of the recognition interface between the islet amyloid polypeptide and insulin. , 2006, Angewandte Chemie.

[122]  P. Scheltens,et al.  Risk of dementia in diabetes mellitus: a systematic review , 2006, The Lancet Neurology.

[123]  M. Reger,et al.  Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[124]  S. Kahn,et al.  Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide. , 2005, Diabetes.

[125]  D. Bennett,et al.  Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. , 2004, Archives of neurology.

[126]  B. Frier,et al.  The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. , 2004, European journal of pharmacology.

[127]  Ronald C Petersen,et al.  Increased risk of type 2 diabetes in Alzheimer disease. , 2004, Diabetes.

[128]  M. R. Nilsson,et al.  Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes? , 2004, Diabetologia.

[129]  W. Duckworth,et al.  An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures. , 2003, Diabetes.

[130]  P. Wesseling,et al.  Heparan sulphate proteoglycans in Alzheimer's disease and amyloid‐related disorders , 2003, The Lancet Neurology.

[131]  K. Conde-Knape.  Heparan sulfate proteoglycans in experimental models of diabetes: a role for perlecan in diabetes complications , 2001, Diabetes/metabolism research and reviews.

[132]  J. Finnerty,et al.  The prohormone convertase enzyme 2 (PC2) is essential for processing pro-islet amyloid polypeptide at the NH2-terminal cleavage site. , 2001, Diabetes.

[133]  S. Kahn,et al.  beta-cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes. , 2000, Diabetes.

[134]  M. Hoenig,et al.  A feline model of experimentally induced islet amyloidosis. , 2000, The American journal of pathology.

[135]  N. Eberhardt,et al.  S20G mutant amylin exhibits increased in vitro amyloidogenicity and increased intracellular cytotoxicity compared to wild-type amylin. , 2000, The American journal of pathology.

[136]  C. Betsholtz,et al.  Islet amyloid polypeptide (amylin)-deficient mice develop a more severe form of alloxan-induced diabetes. , 2000, American journal of physiology. Endocrinology and metabolism.

[137]  S. Kahn,et al.  Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. , 1999, Diabetes.

[138]  T. Sanke,et al.  Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in Type 2 (non-insulin-dependent) diabetic patients , 1991, Diabetologia.

[139]  J. Rothbard,et al.  Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[140]  R. Turner,et al.  Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[141]  C. Wernstedt,et al.  A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. , 1986, Biochemical and biophysical research communications.

[142]  A. Cohen,et al.  Electron Microscopic Observations on a Fibrous Component in Amyloid of Diverse Origins , 1959, Nature.

[143]  S. M. de la Monte,et al.  Early-Stage Alzheimer's Disease Is Associated with Simultaneous Systemic and Central Nervous System Dysregulation of Insulin-Linked Metabolic Pathways. , 2019, Journal of Alzheimer's disease : JAD.

[144]  J. Morley,et al.  Metformin Improves Learning and Memory in the SAMP8 Mouse Model of Alzheimer's Disease. , 2019, Journal of Alzheimer's disease : JAD.

[145]  Yan-Mei Huang,et al.  Human Amylin: From Pathology to Physiology and Pharmacology. , 2019, Current protein & peptide science.

[146]  Hyoung-Gon Lee,et al.  Neuroprotective Effects of the Amylin Analog, Pramlintide, on Alzheimer's Disease Are Associated with Oxidative Stress Regulation Mechanisms. , 2019, Journal of Alzheimer's disease : JAD.

[147]  Zhaojun Wang,et al.  Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease. , 2018, Biochemical and biophysical research communications.

[148]  Y. Park.  The role of Fas-mediated apoptotic pathway in amyloid-induced beta-cell death , 2015 .

[149]  W. H. Yu,et al.  Promoting Autophagic Clearance: Viable Therapeutic Targets in Alzheimer’s Disease , 2014, Neurotherapeutics.

[150]  D. Westaway,et al.  Actions of -Amyloid Protein on Human Neurons Are Expressed through the Amylin Receptor , 2010 .

[151]  Chih-Cheng Hsu,et al.  Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. , 2011, Journal of Alzheimer's disease : JAD.

[152]  S. Dry,et al.  but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. , 2009 .

[153]  D. Raleigh,et al.  Access the most recent version at doi: 10.1110/ps.48702 References , 2000 .

[154]  P. Westermark.  Amyloid and polypeptide hormones: What is their interrelationship? , 1994 .

[155]  J. Polak,et al.  The genesis of apudamyloid in endocrine polypeptide tumours: histochemical distinction from immunamyloid , 1972, Virchows Archiv. B, Cell pathology.